Back to the Drug Development Pipeline

VX-371 (formerly P-1037)

Phase Two

Phase Two

Therapeutic Approach

Mucociliary Clearance

VX-371 is a drug that blocks the sodium channel in airway cells. By blocking this channel, the drug may prolong the duration that fluid in the airways can be maintained after hypertonic saline use. The more fluid in the lungs, the thinner the mucus and the easier it is to clear. 


A phase 2 trial is underway.


This program is sponsored by Vertex Pharmaceuticals Inc. and Parion Sciences and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT). It is being conducted within CFFT's Therapeutics Development Network.

Contact us about VX-371 (formerly P-1037) >